

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) A composition for topical or transdermal administration consisting essentially of: (i) nicotine, caffeine or hydrocortisone; and (ii) Gilsonite oil, and wherein Gilsonite oil is the major proportion ingredient.
2. - 5. (Canceled)
6. - 36. (Canceled)
37. (Previously Presented) A composition for topical or transdermal administration comprising: (i) nicotine, caffeine or hydrocortisone; and (ii) about 1 to about 80 wt % Gilsonite oil having a viscosity of about 5 to 1,000 cps at 25°C, and a specific gravity of about 0.8 to 0.95.
38. (Previously Presented) The composition of claim 37, wherein the Gilsonite oil has a viscosity of about 5 to 100 cps.
39. (Previously Presented) The composition of claim 37, wherein the Gilsonite oil is about 2 to about 50 wt % of the composition.
40. (Previously Presented) The composition of claim 37, wherein the composition further comprises pharmaceutically acceptable additives selected from the group consisting of excipients, preservatives, antioxidants, fragrances, emulsifiers, dyes, adhesives, polymers, and additional penetration enhancers.

41. (New) A composition for topical or transdermal administration consisting of: (i) nicotine, caffeine or hydrocortisone; and (ii) Gilsonite oil.
42. (New) A pharmaceutical composition for topical or transdermal administration comprising:
- (i) nicotine, caffeine or hydrocortisone; and
  - (ii) about 10 to 90 wt % Gilsonite oil having a viscosity of about 5 to about 1,000 cps at 25°C., and specific gravity of about 0.8 to 0.95.
43. (New) The pharmaceutical composition of claim 42, wherein the Gilsonite oil is about 20 to 80 wt % of the composition.